Angie Price

Detail-oriented senior clinical research professional with exceptional communication, leadership, and project management skills. Proven ability to handle multiple tasks effectively and efficiently in fast-paced environments and advance medical knowledge through meticulous research and trial management. Known for collaborative approach and ability to adapt seamlessly to evolving project requirements. Highly skilled in data interpretation, protocol adherence, and regulatory compliance. Recognized for taking a proactive approach to identifying and addressing issues, focusing on optimizing processes, and supporting team objectives.

• APRN, 0371690, ANCC, 08/31/27
• RN, CRNP-Adult, R208399, State of Maryland, 07/28/26
• BLS certification, 01/26

• American Association for the Study of Liver Diseases, 2004-Present
• Sigma Theta Tau Nursing Honor Society, 2018-Present

• DNP
• MSN
• CRNP

• Sneller, L., Lin, C., Price, A., Kottilil, S., Chua, J., RNA interference therapeutics for chronic hepatitis B: Progress, challenges, and future prospects., Microorganism, 12, 599, 2024
• Price, A., Nelson, A., Ghosh, A., Kottilil, S., Chua, J., A phase 2 open-label study of ledipasvir/sofosbuvir for 12 weeks in subjects with hepatitis B virus infection., Journal of Medical Virology, 95, e28105, 2023
• Price, A., Bundy, E., Gross, C., Clark, K., Quality improvement targeting early phase of hepatitis C care delivery., The Journal for Nurse Practitioner, 16, 267-270, 2020
• Wilson, E., Covert, E., Hoffmann, J., Comstock, E., Emmanuel, B., Tang, L., Husson, J., Chua, J., Price, A., Mathur, P., Rosenthal, E., Kattakuzhy S., Masur, H., Kottilil, S., A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY)., Journal of Hepatology, 71, 498-504, 2019
• Price, A., Gross, C., Akoth, E., Wilson, E., Osinusi, A., Kottilil, S., Supervised ART interruption to allow HCV therapy with DAAs in HIV/HCV co-infected subjects., Virology Research Journal, 1, 17-20, 2017
• Kattakuzhy S., Gross C., Emmanuel B., Teferi G., Jenkins V., Silk R., Akoth E., Thomas A., Ahmed C., Espinosa M., Price A., Rosenthal E., Tang L., Wilson E., Bentzen S., Masur H., Kottilil S., the ASCEND Providers., Expansion of treatment for hepatitis C virus infection by task shifting to community-based nonspecialist providers: A nonrandomized clinical trial., Annals of Internal Medicine, 167, 311-318, 2017
• Gross, C., Akoth, E., Price, A., Kattakuzhy, S., Silk, R., Rosenthal, E., HIV/HCV Co-infection: Overcoming barriers to treatment., Journal of Association of Nurses in AIDS Care, 27, 524-529, 2016
• Kattakuzhy, S., Wilson, E., Sidharthan, S., Sims, Z., McLaughlin, M., Price, A., Silk, R., Gross, C., Akoth, E., McManus, M., Emmanuel, B., Shrivastava, S., Tang, L., Nelson, A., Teferi, G., Chavez, J., Lam, B., Mo, H., Osinusi, A., Polis, M. A., Masur, H., Kohli, A., Kottilil, S., Moderate sustained virologic response rates with 6-week combination directly acting anti-hepatitis C virus therapy in patients with advanced liver disease., Clinical Infectious Diseases, 62, 440-447, 2016
• Wilson, E. M., Kattakuzhy, S., Sidharthan, S., Sims, Z., Tang, L., Mclaughlin, M., Price, A., Nelson, A., Silk, R., Gross, C., Akoth, E., Mo, H., Subramanian, G. M., Pang, P. S., McHutchinson, J. G., Osinusi, A., Masur, H., Kohli, A., Kottilil, S., Successful retreatment of chronic HCV genotype-1 infection with ledipasvir and sofosbuvir after initial short course therapy with direct-acting antiviral regimens., Clinical Infectious Diseases, 62, 280-288, 2016
• Kohli, A., Kattakuzhy, S., Sidharthan, S., Nelson, A., Mclaughlin, M., Seamon, C., Wilson, E., Meissner, E., Sims, Z., Silk, R., Gross, C., Akoth, E., Tang, L., Price, A., Jolley, T., Emmanuel, B., Proschan, M., Teferi, G., Chavez, J., Abbott, S., Osinusi, A., Mo, H., Polis, M., Masur, H., Kottilil, S., Four-week direct-acting antiviral regimens in noncirrhotic patients with hepatitis C virus genotype 1 infection: An open-label, nonrandomized trial., Annals of Internal Medicine, 163, 899-907, 2015
• Osinusi, A., Townsend, K., Kohli, A., Nelson, A., Seamon, C., Meissner, E. G., Bon, D., Silk, R., Gross, C., Price, A., Sajadi, M., Sidharthan, S., Sims, Z., Herrmann, E., Hogan, J., Teferi, G., Talwani, R., Proschan, M., Jenkins, V., Kleiner, D. E., Wood, B. J., Subramanian, G. M., Pang, P. S., McHutchison, J. G., Polsi, M. A., Fauci, A. S., Masur, H., Kottilil. S., Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV coinfection., JAMA, 313, 1232-1239, 2015
• Yachimski, P., Wani, S., Givens, T., Howard, E., Higginbotham, T., Price, A., Berman, K., Hosford, L., Katcher, P. M., Ozanne, E., Perzan, K., Hur, C., Preference of endoscopic ablation over medical prevention of esophageal adenocarcinoma by patients with Barrett’s esophagus., Clinical Gastroenterology and Hepatology, 13, 84-90, 2015
• Shiffman, M. L., Salvatore, J., Hubbard, S., Price, A., Sterling, R. K., Stravitz, R. T., Luketic, V. A., Sanyal, A. J., Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha., Hepatology, 46, 371-379, 2007
• Stravitz, R. T., Chung H., Sterling, R. K., Luketic, V. A., Sanyal, A. J., Price, A. S., Purrington A., Shiffman, M. L., Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C., American Journal of Gastroenterology, 100, 1415-1419, 2005
• Price, A. S., Primary and secondary prevention of colorectal cancer., Gastroenterology Nursing, 26, 73-81, 2003

• Viral Hepatitis, Nurse Practitioner Association of Maryland Fall Conference, 11/22
• Ledipasvir/Sofosbuvir in Chronic Hepatitis B Provides Modest Antiviral Activity, The Liver Meeting 2020 Poster Presentation, 11/20
• Safety, Tolerability, and Antiviral Activity of Ledipasvir/Sofosbuvir for Hepatitis B Infection, The Liver Meeting 2019 Poster Presentation, 11/19
• Quality Improvement Targeting Early Phase of Hepatitis C Care Delivery, Annual Nursing Evidence-Based Practice and Research Conference, 03/19
• The Intersection of HIV and Other Co-morbidities, Annual Mid Atlantic AIDS Education and Training Center & Maryland Department of Health, 10/18-10/19